Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 – Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Vinflunin (de)
- Vinflunina (it)
- Vinflunine (nl)
- Vinflunine (en)
|
rdfs:comment
| - Vinflunin ist ein Chemotherapeutikum zur Behandlung von fortgeschrittenen Krebserkrankungen. Der Arzneistoff ist ein fluorierter Abkömmling des Vinorelbins und wurde von dem französischen Unternehmen Laboratoires Pierre Fabre in Castres entwickelt. (de)
- La vinflunina (nome commerciale JAVLOR) è un derivato fluorurato di un alcaloide della Vinca, utilizzato come chemioterapico ad azione antimitotica, nella cura del carcinoma avanzato o metastatico dell'urotelio. La vinflunina è stata scoperta da scienziati del centro di ricerca Pierre Fabre in collaborazione con esperti e ricercatori del Centro Nazionale Francese per la Ricerca Scientifica (CNRS). (it)
- Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 – Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States. (en)
- Vinflunine (INN) is een geneesmiddel voor de behandeling van kanker van het urinewegstelsel, meer specifiek gevorderd of gemetastaseerd overgangscelcarcinoom van het . Vinflunine wordt voorgeschreven als behandeling met platinabevattende geneesmiddelen niet volstaat of niet mogelijk is. Javlor is een geconcentreerde oplossing voor intraveneuze infusie en bevat het ditartraat van de actieve stof vinflunine. De Europese Commissie heeft op 21 september 2009 een vergunning verleend aan Pierre Fabre Médicament om Javlor in de Europese Unie op de markt te brengen. (nl)
|
foaf:depiction
| |
dct:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
ATC suffix
| |
ATC prefix
| |
c
| |
CAS number
| |
ChEBI
| |
ChEMBL
| |
ChemSpiderID
| |
DrugBank
| |
F
| |
H
| |
IUPAC name
| - methyl - 4-- 15-[- 4-- 8-- 1,3,4,5,6,7,8,9-octahydro- 2,6-methanoazecino[4,3-b]indol- 8-yl]- 3-hydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidine- 3-carboxylate (en)
|
legal status
| |
n
| |
O
| |
PubChem
| |
routes of administration
| |